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Dear Editor,
Response to letter from Dr J. De Vries
and Dr M. Drent. Respir Med Editorial
2000; 94: 187–189
De Vries and Drent address important aspects of the
differences between and the problems with ’quality of life’
(QOL) and ’health-related quality of life’ (HRQOL)
measurement. I agree on the necessity to strengthen focus
on the differences between the disease specific and the
generic instruments.
The letter from De Vries and Drent, especially the
references, makes one happy to learn how far the Dutch
have come in the process of validating disease-specific
questionnaires, especially since this is in a relatively small
language and culture, concerning the size of the population.
What was stressed in the editorial was the fact that we have
developed some very useful generic and disease-specific
instruments, but this has been achieved by fiery souls from
different academies only. The present status is that we have
sucient knowledge to conduct studies with HRQOL and
QOL measurements, and what was stressed in the editorial
was the fact that HRQOL questionnaires have been
developed for a minority of diseases only and only in few
languages and cultures. In my opinion, this is the major
factor limiting the propagation of HRQOL measurements,
and that was why the paper by De Vries et al. (1) was
welcomed. It pointed to alternative methods e.g. the focus
group, in cases where no specific questionnaire exists.
I can fully agree with De Vries and Drent on the necessity
of cultural appropriateness, or in other words, cultural
translation of questionnaires. In fact I found this aspect so
important that it was focused on in the editorial title (2). At
present we do have HRQOL questionnaires for several
diseases, often in the English or American languages. But
we need instruments for the investigation of minorities
concerning language, e.g. Dutch or ethnicity, for examples,
Inuit, and the task to produce these instruments seems
tremendous. That is why alternatives are needed and
proposals are welcome. This also holds for the specifica-
tions we have to demand from our generic questionnaires
and that is why the SF-36 has an advantage, probably being
the one questionnaire validated and translated into most
languages and cultures, thus facilitating transcultural
comparisons of results.
F. MADSEN
Department of Internal Medicine,
University of Copenhagen, Frederiksberg, Denmark
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Dear Editor,
Re: Dose proportionality of fluticosone
proportionate hydrofluoroalkane
pressurized metered dose inhalers
(pMDIS) and comparability with
chlorofluorocarbon pMDIS [Respir Med
2000; 94 (Suppl. B): S10–S16]I read with interest the recent article by Kunka et al. which
concluded that HFA and CFC formulations of fluticasone
propionate pMDI produced similar lung deposition and no
difference in systemic exposure at microgram equivalent
doses (1). The conclusion of similar lung deposition with
the 125 mg formulation, on the basis of lung bio-
availability, is not supported by the ratio of HFA :CFC
for plasma fluticasone propionate concentration as area
under curve: 0?67 (90% CI 0?57–0?79). For the same 125 mg
formulation, despite the difference in plasma fluticasone
propionate concentration, there appeared to be no differ-
ence in the uncorrected 24-h urinary cortisol excretion,
where the ratio was found to be 1?04 (95% CI 0?82–1?32). It
is conventional practice to report 24-h urinary cortisol
corrected for creatinine excretion. It also seems bizarre that
the investigators have gone to all the trouble of collecting
the serial 24-h plasma fluticasone propionate concentration,
but appear to have omited collecting blood samples over
the same time profile for 24-plasma cortisol, as this would
have permitted proper pharmacokinetic/pharmacodynamic
modelling.
Furthermore, fluticasone propionate was administered as
single doses, and since it has a large volume of distribution,
with preferential partitioning in to the systemic tissue
compartment rather than blood (due to its high lipophili-
city), it would be more clinically relevant to evaluate what
happens with chronic dosing at steady-state, where there
would be a much greater degree of adrenal suppressioin due
to equilibration between the two compartments (2). After-
all, in real life, patients take fluticasone repeatedly twice
daily, not as a single dose. In this situation it is more likely
that differences between the two formulations would
become evident, as suggested by differences between the
pharmacokinetic profiles for the 125 mg formulation in the
study by Kunka.
In this respect, a previous evaluation was made in healthy
volunteers, where steady-state twice daily administration of
HFA and CFC fluticasone propionate (250 mg formula-
tions) were given in doses of 500, 1000 and 2000 mg daily,fibrosis: which measure should be used? Respir Med
2000; 94: 273–278.
2. Madsen F. Quality of life questionnaires for all
respiratory diseases, every language and ethnic minority,
are alternatives available? Respir Med 2000 94: 187–189.
LETTERS TO THE EDITOR 161and placebo (3). These results showed that the lung bio-
availability of CFC fluticasone propionate was greater
(P50?05) than the HFA formulation for both overnight
urinary cortisol corrected for creatinine. 1?9-fold (95% CI
1?2–3?2) as well as for early morning urinary cortisol
corrected for creatinine: 1?8-fold (95% CI 1.1 – 2?8).
Moreover, for all three doses together there were signifi-
cantly (P50?001) more individual low values for overnight
urinary cortisol excretion5 10 nmol 10 h71 with the CFC
formulation (31%) compared with the HFA formulation
(15%), or compared to placebo (0%). It is also curious that
Kunka et al. chose not to cite this article in this paper in
their list of references, particularly as our results contradict
their own findings.
In view of the discrepancies between the single dose
pharmacokinetic and pharmacodynamic data of Kunka
et al., along with previous chronic dosing data suggesting
differences in lung bio-availability between the HFA and
CFC formulations, one would have to cast serious doubts
on the validity of the conclusions of Kunka et al. that the
two formulations exhibit similar lung deposition and no
difference in systemic exposure at microgram equivalent
doses.
B. J. LIPWORTH
Asthma and Allergy Research Group,
Department of Clinical Pharmacology,
Ninewells Hospital and Medical School,
University of Dundee,
Dundee, DD1 9SY, U.K.
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Dear editor,
Response to letter from Professor B. J.
Lipworth Re: Paper by Kunka et al.
[Respir Med 2000; 94 (Suppl. B):
S10–S16]
Dr Lipworth’s comments focus on urinary cortisol data he
presented in a letter to another journal (1). We are notsurprised that findings based on cortisol do not agree with
our measurements based upon plasma fluticasone propio-
nate (FP) AUC data (2). This is due to a number of factors
including the nonlinear sigmoid relationship between these
two variables (3). Consequently, it has been shown that
cortisol measurements alone cannot be used to reliably
quantify the systemic exposure to corticosteroids and direct
pharmacokinetic measurements should always be used (4).
In addition the type of cortisol data cited by Dr Lipworth
(1) was not based on robust methodology. Early morning
and overnight urinary cortisol requiring correction for
creatinine are indirect measurements and have not been
validated as a means of comparing the bio-availability of
corticosteroids in healthy subjects (5,6). The imprecision
and variability in these parameters is high and they have
not been shown to accurately predict the degree of
corticosteroid systemic exposure as assessed by direct
pharmacokinetic measurements (4). Correction for creati-
nine is applied to account for incomplete urine collections,
but was not required in our study because urine was
collected for a full 24-h period in closely supervised
institutionalized subjects (2). Furthermore, since the
relationship between systemic exposure to corticosteroids
and changes in cortisol is described by a sigmoid curve, the
dose range selected determines the position on the curve
and whether the change in cortisol is smaller or larger than
the accompanying change in corticosteroid plasma AUC
(4). The consequence of this is that in comparing the
relative effects on cortisol for two inhaled formulations the
difference observed is highly dependent on the doses
selected and the study design. This is illustrated in the data
cited by Dr Lipworth (1) where cortisol measurements were
not able to detect a difference when the dose doubled from
250mg b.i.d. to 500 mg b.i.d. There were also no significant
differences found between the HFA and CFC formulations
at two of the three dose levels (250 mg b.i.d. and 2000 mg
b.i.d.) and little evidence of dose proportionality. Although
the study was described as placebo-controlled and single-
blind (1) it is dicult to see how this could be accomplished
without the use of placebo inhalers and using an escalating-
dose design. In the other reference cited the studies were of
similar design, creatinine-corrected overnight cortisol ex-
cretion and morning cortisol were used to support
conclusions that also do not agree with pharmacokinetic
data. Lung deposition was claimed to differ by five-fold for
FP MDI plus spacer compared to a dry powder inhaler and
two-fold for FP MDI plus spacer compared to FP MDI
without spacer (7). These conclusions are unlikely for the
following reasons. Firstly, although a spacer removes larger
particles of FP and reduces oropharyngeal deposition, the
respirable FPM dose is essentially unchanged (8). Secondly,
the absolute bio-availability for the FP Diskus1 dry
powder inhaler has been reported as 17% (95% CI: 14-
20%) based on pharmacokinetic data (9). Therefore, a five-
fold increase would imply that 100% lung deposition could
be attained with an MDI plus spacer, whereas only 20%
deposition has been reported (10). The conclusions from
our study (2), of similar lung deposition and systemic
exposure for FP CFC and HFA MDIs, have been
confirmed in another report (11) that compared FP plasma
